Protein Diagnostic Predicts Differential Treatment Outcomes for Lung Cancer
The VeriStrat specimen collection and shipping kit from Biodesix, Boulder, Colo, facilitates specimen collection for the noninvasive, blood-based VeriStrat protein diagnostic. The test guides therapy decisions for non-small-cell lung cancer patients by predicting differential treatment outcomes between chemotherapy and the targeted drug erlotinib (Tarceva), two types of therapies for second-line treatment of nonoperable, advanced non-small-cell lung cancer (NSCLC). Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is commonly used in NSCLC patients who harbor an EGFR mutation. VeriStrat provides information for oncologists to help determine whether targeted therapy may be appropriate for NSCLC patients without an EGFR mutation, or for those whose EGFR status is unknown. For more information, visit Biodesix.